GSK plc (NYSE:GSK) Shares Purchased by IFG Advisory LLC

IFG Advisory LLC lifted its position in GSK plc (NYSE:GSK) by 12.6% during the second quarter, HoldingsChannel.com reports. The fund owned 14,605 shares of the pharmaceutical company’s stock after acquiring an additional 1,638 shares during the period. IFG Advisory LLC’s holdings in GSK were worth $562,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. JTC Employer Solutions Trustee Ltd boosted its stake in shares of GSK by 71.3% in the first quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock worth $909,063,000 after acquiring an additional 8,800,822 shares during the last quarter. Fisher Asset Management LLC boosted its stake in shares of GSK by 10.6% in the fourth quarter. Fisher Asset Management LLC now owns 15,036,881 shares of the pharmaceutical company’s stock worth $557,267,000 after acquiring an additional 1,436,488 shares during the last quarter. Primecap Management Co. CA boosted its stake in shares of GSK by 0.3% in the fourth quarter. Primecap Management Co. CA now owns 12,089,370 shares of the pharmaceutical company’s stock worth $448,032,000 after acquiring an additional 30,600 shares during the last quarter. Mondrian Investment Partners LTD boosted its stake in shares of GSK by 37.8% in the first quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock worth $236,250,000 after acquiring an additional 1,512,442 shares during the last quarter. Finally, Equity Investment Corp boosted its stake in shares of GSK by 4.8% in the first quarter. Equity Investment Corp now owns 3,398,571 shares of the pharmaceutical company’s stock worth $145,697,000 after acquiring an additional 155,312 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GSK. Citigroup raised GSK to a “strong-buy” rating in a research note on Monday, June 24th. Barclays raised GSK to a “hold” rating in a research note on Tuesday, August 27th. UBS Group lowered GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Jefferies Financial Group boosted their price objective on GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research note on Tuesday, July 2nd. Finally, Berenberg Bank raised GSK to a “strong-buy” rating in a research note on Thursday, June 20th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $50.00.

GSK Stock Performance

Shares of GSK stock opened at $43.91 on Monday. GSK plc has a 52 week low of $33.67 and a 52 week high of $45.92. The business’s fifty day simple moving average is $40.11 and its 200-day simple moving average is $41.58. The firm has a market cap of $91.00 billion, a PE ratio of 15.91, a price-to-earnings-growth ratio of 1.42 and a beta of 0.64. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.99.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 10th. Stockholders of record on Friday, August 16th will be paid a $0.3843 dividend. This represents a $1.54 annualized dividend and a dividend yield of 3.50%. The ex-dividend date is Friday, August 16th. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is 54.71%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.